Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

doses, and treatment regimens. Each of the currently ongoing and planned studies is aimed at gaining wider experience for this novel treatment approach and to bring us closer towards a causal and disease-modifying therapy for a broad range of allergic diseases."

Cytos Biotechnology will host a conference call and Q&A session today, Tuesday, March 13, 2007 at 9.30 am CET to discuss the study findings.

To access the conference call, please dial the following numbers:

Europe +41 91 610 56 00

U.S. +1 866 291 41 66

U.K. +44 207 107 06 11

The conference call will be held in English and will also be accessible by webcast on the internet. You may follow the call live or have it replayed later on demand. To access the webcast and the presentation, please follow the link provided on our homepage www.cytos.com. The presentation slides will be available for download 30 minutes prior to the conference call.

About the phase IIa study and the analysis

The randomized, double-blind and placebo-controlled phase IIa study included 40 male and female patients aged 18 to 65 and suffering from mild to moderate seasonal allergic rhinitis due to grass pollen allergy. Upon entry into the study, the allergic status of the individual participants was recorded by the conjunctival provocation test, a commonly used allergy test. The study participants were randomized into 4 treatment groups with 10 patients each and received 6 weekly injections of either i) 300 ?g CYT003-QbG10, ii) 300 ?g CYT003-QbG10 plus Alum, iii) placebo (PBS or Alum), or iv) 300 ?g CYT003-QbG10 plus grass pollen extract (this last group was handled exploratory and open-label). Two weeks after the last dose, the allergic status of the patients was again assessed by the conjunctival provocation test. All 40 patients were included into the analysis.

Ab
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/3/2015)... 2015 Today, the Partnership for Prescription ... biopharmaceutical research companies, unveiled a redesigned website ... patients and caregivers with faster, easier access to ... patient assistance programs. Since its ... to engage, educate and empower patients and caregivers ...
(Date:3/3/2015)... -- - CPhI and P-MEC China 2015 ... Shanghai, China - The 15th ... held at Shanghai New International Expo Center, on 24th June, ... Worldwide and was introduced to China in 2001. It has ... companies and global pharmaceutical industry over the past 15 years. ...
(Date:3/3/2015)... March 3, 2015  Tru-D SmartUVC will exhibit ... for Perioperative Registered Nurses, Surgical Conference and Expo ... during Patient Safety Awareness Week March 7 through ... safe clinical practice and professional development. ... - http://photos.prnewswire.com/prnh/20150302/178998LOGO   Tru-D ...
Breaking Medicine Technology:Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 215th Anniversary, Be Part of Chinese Pharma Dream 215th Anniversary, Be Part of Chinese Pharma Dream 3Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 2Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 3
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
... 9, 2011 Quest Diagnostics, the world,s leading provider of ... today announced its national sponsorship of Choose You®, the American ... putting their health first and making healthy lifestyle choices to ... in 3 American women will get cancer in her lifetime, ...
Cached Medicine Technology:Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2Quest Diagnostics Sponsors American Cancer Society's Choose You® Movement 2Quest Diagnostics Sponsors American Cancer Society's Choose You® Movement 3
(Date:3/3/2015)... The combinatorial, multi-gene GeneSight test has ... for patients with depression, and their use of ... genes that comprise the test, according to a ... and Assurex Health, and published online by The ... of the GeneSight Psychotropic test is based on ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 -- vRad ( Virtual Radiologic ... today announced that Arlene Sussman, MD, a highly regarded ... live webinar to explore how telemedicine best practices allow ... services for women virtually anywhere. Click here ... Line” on March 4, 2015 at 1:00 pm CT. ...
(Date:3/3/2015)... In a segment that aired Monday, March ... Vedantam shared research from the Wharton School ... hand-hygiene compliance that occurs over the course of a healthcare ... in part by alerts on healthcare workers’ badges that remind ... a patient’s room. , “Over the course of a ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Retrofit ... epidemic at America’s leading corporations, today announces the appointment ... senior executive positions. CEO Mary Pigatti has ... innovation and employee engagement for the fast-growing company, which ... to watch for 2015. , “Retrofit is thrilled ...
(Date:3/3/2015)... 2015 The FSH Society , ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), ... . The purpose of the campaign is to spread ... most common forms of muscular dystrophies. , To ... the FSH Society will begin sharing impactful photographs of ...
Breaking Medicine News(10 mins):Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 2Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 2Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 4Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 3
... Scientists know little about how the brain creates and ... obstacle in the effort to develop treatments for emotional ... is in its infancy," says Howard Hughes Medical Institute ... continue to take an enormous toll on human society." ...
... heart risk, leaked documents suggest , SATURDAY, Feb. 20 ... Avandia raises users, odds for heart attack and heart ... to confidential government reports. , The New York ... U.S. Food and Drug Administration that find that if ...
... ... it,s new shop in Beverly Hills, featuring old style barbering, straight razor shaves, in a ... ... today the official opening of its Beverly Hills store located at 9635 Brighton Way, Beverly ...
... ... chief loss mitigator for IndyMac Banks HELOC division, conducted a short sale continuing ... Honish is the first bank employee approved by any state to conduct a ... only course on the subject of short sales taught from this perspective. The ...
... ... ... , ... , ...
... ... ... ... , ...
Cached Medicine News:Health News:David Anderson to discuss what model organisms can teach us about emotion 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 3Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 4Health News:The Classic Shave Company Announces the Opening of Beverly Hills Shop 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 2Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 4Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 5Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: